The E domain of fibrinogen represents the central region of the protein that, after the removal of fibrinopeptides from the N-termini of its ␣ chains by thrombin, orders the noncovalent assembly of fibrin units into a half-staggered array. This structural organization is accomplished purely through noncovalent binding between the E domain of one molecule and the distal D domains of two others. The process of assembly has a physiologically important up-regulatory effect on the next enzymatic phase of blood coagulation, which is the factor XIII a -catalyzed end-to-end ligation of the ␥ chains at the D domains of the protein. Fibrin assembly, as well as the acceleration of the factor XIII a reaction, could be prevented by Gly-Pro-Arg-Pro, a homologue of the natural sequence of amino acids at the N termini of ␣ chains in the E domain. We have now succeeded with a simple double-headed ligand, bis(Gly-Pro-Arg-Pro-amido)polyethylene glycol, in fully replacing the regulatory functions of the large E domains of the native protein.
The clotting of fibrinogen in human plasma is regulated by a remarkable series of biochemical controls (for a recent summary, see ref. 1). The key for unlocking the self-assembly potential of fibrinogen in its conversion to fibrin is the limited proteolytic attack by thrombin that, through removal of the N-terminal fibrinopeptide moieties (2, 3) , generates a new set of Gly end groups (4, 5) . The short sequence of amino acids including and following the newly exposed N-terminal Gly residues of the two ␣ chains of fibrin (6, 7) seems to be the necessary ligand for causing the noncovalent, reversible aggregation of fibrin into a clot (5, 8, 9) . Gly-Pro-Arg-Pro, which resembles the natural Gly-Pro-Arg-Val sequences (knobs) in the fibrinopeptide A-denuded central E domain of fibrin, can prevent clot formation (10) . The tetrapeptide blocks the polymerization pockets or holes located in the ␥ chains at the two D end domains of the protein (11) (12) (13) (14) (15) (16) . It is important to bear in mind that these polymerization pockets are present not only in fibrin but also in the parent fibrinogen molecule, i.e., thrombin action is not required for opening them for Gly-ProArg-Pro to bind. Thus, the two N-terminal knobs in the central E domain of the protein unmasked by thrombin seem to act as a bifunctional ligand for the end-to-end, noncovalent assembly of fibrin units into the well known, half-staggered, double array of protofibrils seen in the electron microscope (17, 18) . This brings together each E domain with the D domains of two other molecules.
The assembly process, as organized by the thrombinmodified E domains, imparts a major advantage for the next enzymatic phase of the coagulation cascade, the factor XIII acatalyzed covalent stabilization of fibrin filaments by N (␥-glutamyl)lysine crosslinks. Fibrinogen in solution is about an order of magnitude weaker substrate for factor XIII a than clotted fibrin (19, 20) , which, from the physiological point of view, is obviously an important feed-forward regulatory control. We have recently succeeded in reproducing this unique substrate-level control mechanism by complementation of fibrinogen, and even the purified D fragments, with the thrombin-modified central E portion of the protein (21) . The Gly-Pro-Arg-Pro tetrapeptide prevented complex formation between E and fibrinogen, as well as between E and D, and it also abolished the enhancing effect of E on the crosslinking of fibrinogen or D fragments by factor XIII a .
We reasoned that a synthetic, double-headed Gly-Pro-ArgPro ligand might serve as a polymerizing agent for fibrinogen and as a dimerizing agent for D fragments, and could thereby act as a functional substitute for the E domains in boosting the factor XIII a -dependent crosslinking reactions with intact fibrinogen or with the D fragments as substrates. This report bears out the correctness of the assumption.
compound, which was next deblocked by trifluoroacetic acid (TFA) and coupled to Z-Gly-Pro to give Z-Gly-Pro-Arg(Z) 2 -Pro-0Me, yield 70%, R f ϭ 0.96 (A), 0.81 (B), 0.73 (C), and 0.88 (D). Amino acid analysis gave Gly 1.18 (1), Arg 1 (1), and Pro 1.76 (2) . Deblocking of the methyl ester group was accomplished by saponification with 0.2 M NaOH in 70% aqueous ethanol for 2 h at room temperature to give a 52% yield of Z-Gly-Pro-Arg(Z) 2 -Pro, R f ϭ 0.21 (A), 0.58 (B), 0.59 (C), and 0.70 (D).
Bis(Gly-Pro-Arg-Pro-amido)peg. [CH 3 CH(NH-Pro-ArgPro-Gly)-CH 2 -(OCH 2 CH 2 ) 18 -OCH 2 -CH(NH-Pro-Arg-ProGly)-CH 3 . First, the commercial 0,0Ј-bis(2-aminopropyl)polyethylene glycol of MW 900, containing 2.16 milliequivalent (meq) of amino function per g, was coupled with an equivalent amount of Z-Gly-Pro-Arg(Z) 2 -Pro by published procedures (23, 24) to give the bis-derivatized polyethylene glycol, bis[ZGly-Pro-Arg-(Z) 2 -Pro-amido]peg, which was isolated from a chloroform extract of the product after processing (23) Enzyme-Catalyzed Covalent Ligation with Fibrinogen or with D Fragments as Substrates. Plasminogen-free human fibrinogen (American Diagnostica, Greenwich, CT) was dissolved by addition of water (40 mg͞2 ml) and dialyzed against a buffer of 50 mM Tris⅐HCl, 150 mM NaCl, pH 7.5 (4 liters, 4°C, 20 h). Protein concentration was estimated on the basis of absorbance of E 1%, 280 nm ϭ 15.1 (25) , and the solution was stored at Ϫ70°C. Preparation of D fragments, from the plasmin digest of fibrinogen (26) , was carried out by E. Ang of Northwestern University as previously described (21) . The material was dissolved in the above Tris-NaCl buffer; protein concentration was measured by E 1%, 280 nm ϭ 20 (27) , and the solution was stored at Ϫ20°C. Recombinant human factor XIII A subunits [rA 2 ; MW ϭ 160,000 (28)] was a gift from P. D. Bishop (Zymogenetics, Seattle, WA); the lyophilized powder was taken up in water (12 mg͞ml) and stored in small aliquots at Ϫ70°C. Human ␣-thrombin, a gift from J. W. Fenton III (New York State Dept. of Health, Albany, NY), was stored at Ϫ70°C in 75 mM Tris⅐HCl, 1 mM EDTA, pH 7.5, in aliquots at 500 units͞ml. Hirudin (650 anti-thrombin units͞mg) was purchased from Sigma and stored at Ϫ20°C at 1,000 units͞ml in 50 mM Tris⅐HCl, 150 mM NaCl, pH 7.5. The double-headed bis(Gly-Pro-Arg-Pro-amido)peg ligand was dissolved in water to yield a 40-mM stock solution, which was stored at Ϫ20°C.
Before each experiment, the factor XIII rA 2 zymogen (1.56 M) was activated by treatment with thrombin (25 National Institutes of Health units͞ml) at room temperature (ca. 22°C) for 30 min, when a 2-fold excess of hirudin units over thrombin (50 units of hirudin per ml) was added to quench thrombin activity. Aliquots from this thrombin-activated rA 2 preparation (40 l) were used in the crosslinking experiments. Solutions (24 l) of D fragments were incubated with bis(Gly-Pro-Arg-Pro-amido)peg of varying concentrations at room temperature (Ϸ22°C) for 60 min in the presence of CaCl 2 (2 mM). Then, thrombin-activated rA 2 (1 l) was added, which, on account of Ca 2ϩ in the mixtures, would function immediately as a transamidase to initiate crosslinking (i.e., 2 M D fragment with 0.06 M enzyme). The reaction was terminated at 90 min by addition of EDTA (to 4 mM). Control mixtures were prepared with EDTA (2 mM) replacing CaCl 2 or by omitting the double-headed Gly-Pro-Arg-Pro compound.
In the experiments with fibrinogen, 23-l solutions of the protein were incubated with varying concentrations of bis(GlyPro-Arg-Pro-amido)peg at 37°C for 40 min, when crosslinking was initiated by adding 6 l of CaCl 2 and 1 l of thrombinactivated rA 2 with final concentrations of 3 M for fibrinogen, 0.02 M activated rA 2 , and 2 mM CaCl 2 . Reactions were allowed to proceed for 30 min and were terminated with EDTA (to 4 mM). Appropriate controls without CaCl 2 or the double-headed compound were employed.
For analyzing the crosslinked products of fibrinogen, samples were solubilized in 2% SDS with 40 mM DTT (37°C, 30 min), whereas the formation of crosslinked DD dimers was examined by solubilization in SDS without DTT. SDS͞PAGE (29) was performed in a Mini-Protean II system (Bio-Rad) by using 8 or 10% acrylamide. Scanning of gels and calculation of crosslinking percentages were carried out as previously reported (21) .
Electrophoresis of the crosslinked fibrinogen products in 2% agarose (SeaKem, FMC, Rockland, ME) was performed by the method of Moroi et al. (30) with tube gels in a Bio-Rad Model 150A apparatus (4 h, room temperature, 100 mA for 12 tubes) after solubilizing the samples in 100 mM sodium phosphate, pH 7.1, and 0.1% SDS.
RESULTS AND DISCUSSION
We have shown in an earlier study (21) that mixing nearly equal amounts of the thrombin-modified E fragments, which represent the central domains of fibrin, with intact fibrinogen caused a significant increase in the reactivities of the distal D domains of the protein for crosslinking by coagulation factor XIII a . A similar up-regulatory effect was observed in the presence of E for the reactions of the proteolytically derived D fragments of fibrinogen for the formation of crosslinked DD dimeric products. Because the E fragments did not react with the enzyme, this remarkable substrate-level control was attributed to complex formations between fibrinogen and E, and between D and E. Displaying sufficient stability in nondenaturing electrophoresis, the existence of such complexes could, in fact, be demonstrated in solution. Inasmuch as the kinetic boosting effect of E on the enzymatic crosslinking of fibrinogen or D, and also the formation of fibrinogen:E or D:E complexes was abolished by admixture of the Gly-Pro-Arg-Pro tetrapeptide (21) , it was concluded that contact between the N termini of the thrombin-modified ␣ chain duplex in the central E domains of fibrinogen, comprising the homologous Gly-ProArg-Val sequences, and the distal D domains of the protein was of critical importance. Recently, in a parallel, electronmicroscopic examination of mixtures of fibrinogen with E fragments, linear daisy-chain co-assemblies were seen stretching to lengths of more than 30 fibrinogen units (Y. Veklich, E. Ang, J. Weisel, and L.L., unpublished results).
We reasoned that a double-headed Gly-Pro-Arg-Pro derivative might very well replace the functions of the thrombinmodified E domain of the native clotting protein of plasma in coordinating the binding of two distal D domains. If so, the best test would be to evaluate the effect of the new compound for promoting the crosslinking of fibrinogen or D fragments by factor XIII a . Fig. 1 illustrates the ideas underlying our experimental approach.
The double-headed Gly-Pro-Arg-Pro, synthesized as the functional fibrin E domain mimic, was constructed with a polyethylene glycol tether to which the carboxyl ends of the two C-terminal Pro residues were connected by amide bonds (see Materials and Methods). Good water solubility of the bis(Gly-Pro-Arg-Pro-amido)peg derivative was an obvious advantage, and flexibility of the long polyethylene glycol tether was presumed to facilitate positioning of the Gly-Pro-Arg-Pro (1998) ligands into the polymerization pockets of the D domains without strain. An E-fragment-like enhancement for the enzymatic crosslinking of D domains could be expected only with the proper mole ratios between the concentrations of the double-headed ligand and substrates, be they fibrinogen or D fragments. Formation of ternary complexes necessary to promote the reactions would occur only with a productive mode of binding (see Fig. 1 A and B) . Thus, the influence of bis(Gly-Pro-Arg-Pro-amido)peg on the crosslinking of the substrates, tested with 2 M D or 3 M fibrinogen, had to be explored over a large range of concentrations of the ligand (up to 2 mM). The findings in Fig. 2A (Figs. 3 A and B) . The reactions were monitored by production (37°C, 30 min) of nonreducible ␥␥ dimers on SDS͞polyacrylamide gel. A 5-to 7-fold boosting of reaction rates was recorded at the lower concentrations of the (2 mM) and was allowed to proceed for 90 min at room temperature (Ϸ22°C), and it was terminated by adding EDTA (4 mM). SDS͞PAGE, with ca. 4.5 g of protein per lane, was carried out in 10% acrylamide for A and in 8% acrylamide for B. After staining and drying of gels, densitometry was performed, and the extent of crosslinking as percentages was calculated from the measured intensities of monomeric D and dimeric DD species as DD͞(DϩDD) ϫ 100.
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Proc. Natl. Acad. Sci. USA 95 (1998) double-headed ligand (up to 50 M), but, at higher concentrations, reaction rates fell gradually to the control value seen in the absence of the ligand. In the previous study on the effects of complementation with E fragments (21), for technical reasons, mole ratios of E to fibrinogen or E to D could not be raised high enough beyond demonstrating an apparent saturation by E for enhancing the enzymatic crosslinking reactions. Thus, the downward slopes, seen with bis(Gly-Pro-Arg-Pro-amido)peg as modulator (Figs. 2B and 3B), could not be documented with E. Apart from this, however, the boosting effect of the new, relatively small ligand was similar in every respect to that observed with the proteinderived, large E fragment. It is also interesting that both modulators promoted only the end-to-end crosslinking of the ␥ chains of fibrinogen without enhancing the enzymecatalyzed reaction for the side-by-side crosslinking of ␣ chains. We surmise that the transfer or rolling over of the enzyme from the ␥ chain to the ␣ chain sites in the protein may require the formation of a three-dimensional lattice rather than the linear daisy chain structures generated in mixtures of fibrinogen with E or with the bis(Gly-Pro-Arg-Pro-amido)peg derivative.
Given that fibrinogen [A␣B␤␥] 2 is a disulfide-bonded symmetrical duplex molecule composed of three different constituent chains that are also connected to each other by disulfides (6, 7) , SDS͞PAGE analysis after reduction with DTT is of very limited use for providing information about the true extent of end-to-end crosslinking. Figs. 3 A and B show that, in the presence of the double-headed ligand, as much as 70% of the monomeric ␥ chains could be crosslinked to form nonreducible ␥␥ dimers, compared with ca. 10% in the control. This measure, however, sheds no light on the size of the covalently fused protein structures, and the finding would be compatible with the crosslinking of 70% of the starting fibrinogen monomers into 2 ϫ [A␣B␤␥] 2 dimeric structures or into higherorder polymers with lesser percentages.
An SDS-agarose electrophoretic method, without reduction by DTT (30) , was employed for analyzing the crosslinked products formed in the enzymatic reaction of fibrinogen (3 M) in the presence of varying concentrations (0-2 mM) of double-headed Gly-Pro-Arg-Pro. The results presented in Fig.  4 clearly demonstrate the biphasic influence of the ligand, as predicted from the model for its concentration-dependent, productive and nonproductive mode of binding with fibrinogen ( Fig. 1 A) . Crosslinked oligomeric bands of fibrinogen up to pentamers are marked as 2 -5 on the gels in Fig. 4 , and 1 denotes the starting monomer. The reference material (EDTA control), contained a small amount of dimeric 2 , often seen in commercial preparations. Crosslinked fibrinogens larger than pentamers are marked collectively as n in Fig. 4 , but, on the gel relating to the reaction in the presence of 10 M ligand, even bands representing 15 Crosslinking in the presence of Ca 2ϩ (2 mM) by activated factor XIII (0.02 M) was allowed to proceed at 37°C for 30 min when it was terminated by admixture of EDTA (4 mM). After reduction of the samples with DTT, SDS͞PAGE was performed (applying ca. 12 g of protein per lane) in 10% acrylamide, followed by staining, drying, and densitometric scanning. The extent of the crosslinking of ␥ chains was calculated from the intensities of the monomeric ␥ and dimeric ␥␥ chains as ␥␥͞(␥ϩ␥␥) ϫ 100.
FIG. 4.
Influence of the double-headed bis(Gly-Pro-Arg-Proamido)peg ligand on the degree of covalent polymerization of fibrinogen with factor XIIIa. This experiment was carried out according to the procedure described in the legend to Fig. 3 . However, the reaction products (ca. 40 g per tube) were analyzed, without reduction, by electrophoresis in agarose (2%)͞0.1% SDS, as given in Materials and Methods. (1998) remained by the end of the enzymatic reaction (30 min, 37°C), and a significant portion of the crosslinked polymers was present in very large structures piled up on the top of the gels. These findings are fully in accord with the idea that addition of the bis(Gly-Pro-Arg-Pro-amido)peg derivative to fibrinogen, similar to the observations for mixtures of E fragments with fibrinogen, causes the fibrinogen molecules to assemble noncovalently into long chains. Apparently, this is a prerequisite for favorable reaction with the enzyme at the ␥ chain crosslinking sites of the D domains. Proper alignment of these sites may lower the K M for the enzyme and͞or increase V max for the catalytic turnover.
The thrombin-and Ca 2ϩ -activated coagulation factor XIII belongs to a larger family of transamidases commonly referred to as transglutaminases. Some function extracellularly, others in the intracellular milieu, and they display one of two basic motifs of operation. Crosslinking (x) of proteins (P) in solution by N (␥-glutamyl)lysine side-chain bridges: nP 3 xP n is the simpler motif, exemplified by the formation of copulation plug in rodents by a prostatic transglutaminase (31) or by the clotting of Homarus plasma where the enzyme is released from exploding amoebocytes (32) . The other, more complicated motif is typified by the clotting of human (i.e., vertebrate) fibrin (F) where the noncovalent, reversible assembly of the substrate precedes the enzymatic ligation step: nF º F n 3 xF n . As shown in our previous work (21) and also in the present paper, the preassembly of the substrate can be an important trigger for increasing the rate of the crosslinking reaction. In terms of physiological significance, the D-to-E contactdependent up-regulation of the factor XIII a -catalyzed crosslinking of ␥ chains matches the rate difference for thrombin generation between a normal and a hemophilic plasma. It is remarkable that this complex-regulatory mechanism, built around the large E segment of the native fibrin molecule, could be so effectively reproduced with a relatively small and simple double-headed ligand.
